These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 22780968)

  • 21. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].
    Zou WY; Xu DR; Su C; Chen M; Li J; Luo SK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1868-70, 1873. PubMed ID: 20813688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
    Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
    Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bcr-Abl induces autocrine IGF-1 signaling.
    Lakshmikuttyamma A; Pastural E; Takahashi N; Sawada K; Sheridan DP; DeCoteau JF; Geyer CR
    Oncogene; 2008 Jun; 27(27):3831-44. PubMed ID: 18246120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.
    Gutiérrez P; Delgado MD; Richard C; Moreau-Gachelin F; León J
    Biochem Biophys Res Commun; 1997 Nov; 240(3):862-8. PubMed ID: 9398659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
    Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
    Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
    Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D
    Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
    Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
    Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
    Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
    Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
    Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
    Li Z; Luo J
    Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
    Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
    Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.